2017: grita

Publications 2017

2017 : 62 publications !

Adens A, Landy P, Terriou L, Baillet C, Beron A, Lambert M, Launay D, Huglo D. [Usefulness of nuclear medicine in Erdheim-Chester disease: A Lille experience]. Rev Med Interne. 2017;38:235–42.

Anthony S, Hebel P, Garrel A, Oliveri V, Thieblemont C, Ribrag V, Tilly H, Haioun C, Casasnovas RO, Morschhauser F, Feugier P, Delarue R, Ysebaert L, Sebban C, Broussais F, Damaj G, Nerich V, Jais JP, Salles G, Henry-Amar M, Mounier N. Conduct of epidemiologic studies in French cancer survivors: Methods, difficulties encountered and solutions provided. Lessons learned from the SIMONAL study on long-term toxicities after non-Hodgkin lymphoma treatment. Bull Cancer. 2017;104:221–31.

Arcaini L, Lamy T, Walewski J, Belada D, Mayer J, Radford J, Jurczak W, Morschhauser F, Alexeeva J, Rule S, Cabeçadas J, Campo E, Pileri SA, Biyukov T, Patturajan M, Casadebaig Bravo ML, Trnĕný M. Prospective subgroup analyses of the randomized MCL-002 (SPRINT) study: lenalidomide versus investigator’s choice in relapsed or refractory mantle cell lymphoma. Br J Haematol. 2017;

Artru F, Louvet A, Ruiz I, Levesque E, Labreuche J, Ursic-Bedoya J, Lassailly G, Dharancy S, Boleslawski E, Lebuffe G, Kipnis E, Ichai P, Coilly A, De Martin E, Antonini TM, Vibert E, Jaber S, Herrerro A, Samuel D, Duhamel A, Pageaux GP, Mathurin P, Saliba F. Liver transplantation in the most severely ill cirrhotic patients: A multicenter study in acute-on-chronic liver failure grade 3. J Hepatol. 2017;67:708–15.

Averlant L, Ficheur G, Ferret L, Boule S, Puisieux F, Luyckx M, Soula J, Georges A, Beuscart R, Chazard E, Beuscart JB. Underuse of Oral Anticoagulants and Inappropriate Prescription of Antiplatelet Therapy in Older Inpatients with Atrial Fibrillation. Drugs Aging. 2017;34:701–10.

Baro E, Galperine T, Denies F, Lannoy D, Lenne X, Odou P, Guery B, Dervaux B. Cost-Effectiveness Analysis of Five Competing Strategies for the Management of Multiple Recurrent Community-Onset Clostridium difficile Infection in France. PLoS One. 2017;12.

Beauval N, Antherieu S, Soyez M, Gengler N, Grova N, Howsam M, Hardy EM, Fischer M, Appenzeller BMR, Goossens JF, Allorge D, Garçon G, Lo-Guidice JM, Garat A. Chemical Evaluation of Electronic Cigarettes: Multicomponent Analysis of Liquid Refills and their Corresponding Aerosols. J Anal Toxicol. 2017;41:670–8.

Belaiche S, Décaudin B, Dharancy S, Gautier S, Noel C, Odou P, Hazzan M. Factors associated with the variability of calcineurin inhibitor blood levels in kidney recipients grafted for more than 1 year. Fundam Clin Pharmacol. 2017;

Belaiche S, Décaudin B, Dharancy S, Noel C, Odou P, Hazzan M. Factors relevant to medication non-adherence in kidney transplant: a systematic review. Int J Clin Phar,. 2017;39:582–93.

Belaiche S, Mercier E, Cuny D, Kambia N, Wierre P, Bertoux É, Mascaut D, Azar R, Bataille P, Bourdon F, Mac Namara É, Maisonneuve N, Painchart B, Vrigneau L, Noël C, Décaudin B, Glowacki F. Community pharmacists’ interventions to prevent and screen chronic kidney disease patients. Nephrol Ther. 2017;13:87–92.

Bernard L, Bourdeaux D, Pereira B, Azaroual N, Barthélémy C, Breysse C, Chennell P, Cueff R, Dine T, Eljezi T, Feutry F, Genay S, Kambia N, Lecoeur M, Masse M, Odou P, Radaniel T, Simon N, Vaccher C, Verlhac C, Yessad M, Décaudin B, Sautou V. Analysis of plasticizers in PVC medical devices: Performance comparison of eight analytical methods. Talanta. 2017;162:604–11.

Beuscart JB, Ficheur G, Miqueu M, Luyckx M, Perichon R, Puisieux F, Beuscart R, Chazard E, Ferret L. Co-prescriptions of psychotropic drugs to older patients in a general hospital. Eur Geriatr Med. 2017;8:84–9.

Billon L, Dcaudin B, Pasquier G, Lons A, Deken-Delannoy V, Germe AF, Odou P, Migaud H. Prospective assessment of patients’ knowledge and informational needs and of surgeon-to-patient information transfer before and after knee or hip arthroplasty. Orthop Traumatol Surg Res. 2017;

Bröckelmann PJ, Müller H, Casasnovas O, Hutchings M, von Tresckow B, Jürgens M, McCall SJ, Morschhauser F, Fuchs M, Borchmann P, Moskowitz CH, Engert A. Risk factors and a prognostic score for survival after autologous stem-cell transplantation for relapsed or refractory Hodgkin lymphoma. Ann Oncol. 2017;28:1352–8.

Casasnovas RO, Ysebaert L, Thieblemont C, Bachy E, Feugier P, Delmer A, Tricot S, Gabarre J, Andre M, Fruchart C, Mounier N, Delarue R, Meignan M, Berriolo-Riedinger A, Bardet S, Emile JF, Jais JP, Haioun C, Tilly H, Morschhauser F. FDG-PET-driven consolidation strategy in diffuse large B-cell lymphoma: final results of a randomized phase 2 study. Blood. 2017;130:1315–26.

Castillo-Aguilera O, Depreux P, Halby L, Arimondo PB, Goossens L. DNA Methylation Targeting: The DNMT/HMT Crosstalk Challenge. Biomolecules. 2017;7.

Castillo-Aguilera O, Depreux P, Halby L, Azaroual N, Arimondo PB, Goossens L. Regioselective and efficient halogenation of 4,5-unsubstituted alkyl 3-hydroxypyrrole/3-hydroxythiophene-2-yl-carboxylates. Tetrahedron Lett. 2017;58:2537–41.

Catry E, Bindels LB, Tailleux A, Lestavel S, Neyrinck AM, Goossens JF, Lobysheva I, Plovier H, Essaghir A, Demoulin JB, Bouzin C, Pachikian BD, Cani PD, Staels B, Dessy C, Delzenne NM. Targeting the gut microbiota with inulin-type fructans: preclinical demonstration of a novel approach in the management of endothelial dysfunction. Gut. 2017;

Chamoun K, Choquet S, Boyle E, Houillier C, Larrieu-Ciron D, Al Jijakli A, Delrieu V, Delwail V, Morschhauser F, Hoang-Xuan K, Soussain C. IBRUTINIB MONOTHERAPY IN RELAPSED/REFRACTORY CNS LYMPHOMA: A RETROSPECTIVE CASE SERIES. Neurology. 2017;88:101–2.

Chávez-Talavera O, Baud G, Spinelli V, Daoudi M, Kouach M, Goossens JF, Vallez E, Caiazzo R, Ghunaim M, Hubert T, Lestavel S, Tailleux A, Staels B, Pattou F. Roux-en-Y gastric bypass increases systemic but not portal bile acid concentrations by decreasing hepatic bile acid uptake in minipigs. Int J Obes (Lond). 2017;41:664–8.

Criquet J, Dumoulin D, Howsam M, Mondamert L, Goossens JF, Prygiel J, Billon G. Comparison of POCIS passive samplers vs. composite water sampling: A case study. Sci Total Environ. 2017;609:982–91.

Dreyling M, Morschhauser F, Bouabdallah K, Bron D, Cunningham D, Assouline SE, Verhoef G, Linton K, Thieblemont C, Vitolo U, Hiemeyer F, Giurescu M, Garcia-Vargas J, Gorbatchevsky I, Liu L, Koechert K, Peña C, Neves M, Childs BH, Zinzani PL. Phase II study of copanlisib, a PI3K inhibitor, in relapsed or refractory, indolent or aggressive lymphoma. Ann Oncol. 2017;28:2169–78.

Dreyling M, Santoro A, Mollica L, Leppä S, Follows GA, Lenz G, Kim WS, Nagler A, Panayiotidis P, Demeter J, Özcan M, Kosinova M, Bouabdallah K, Morschhauser F, Stevens DA, Trevarthen D, Giurescu M, Cupit L, Liu L, Köchert K, Seidel H, Peña C, Yin S, Hiemeyer F, Garcia-Vargas J, Childs BH, Zinzani PL. Phosphatidylinositol 3-Kinase Inhibition by Copanlisib in Relapsed or Refractory Indolent Lymphoma. J Clin Oncol. 2017;JCO2017754648.

Ferrand É, Painchart L, Grimandi G, Décaudin B, Bussières JF. [The roles and the impacts of pharmacists in the management of medical devices at the hospital: A literature review]. Ann Pharm Fr. 2017;75:409–19.

Gauthier J, Chantepie S, Bouabdallah K, Jost E, Nguyen S, Gac AC, Damaj G, Duléry R, Michallet M, Delage J, Lewalle P, Morschhauser F, Salles G, Yakoub-Agha I, Cornillon J. [Allogeneic haematopoietic cell transplantation for diffuse large B cell lymphoma: Guidelines from the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC)]. Bull Cancer. 2017;

Gauthier J, Chantepie S, Bouabdallah K, Jost E, Nguyen S, Gac AC, Damaj G, Duléry R, Michallet M, Delage J, Lewalle P, Morschhauser F, Salles G, Yakoub-Agha I, Cornillon J. [Allogeneic haematopoietic cell transplantation for indolent lymphomas: Guidelines from the Francophone Society Bone Marrow Transplantation and Cellular Therapy (SFGM-TC)]. Bull Cancer. 2017;

Gauthier J, Chantepie S, Bouabdallah K, Jost E, Nguyen S, Gac AC, Damaj G, Duléry R, Michallet M, Delage J, Lewalle P, Morschhauser F, Salles G, Yakoub-Agha I, Cornillon J. [Allogeneic hematopoietic cell transplantation for Hodgkin’s disease, mantle cell lymphoma and other rare entities: Guidelines from the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC)]. Bull Cancer. 2017;

Gauthier J, Chantepie S, Bouabdallah K, Jost E, Nguyen S, Gac AC, Damaj G, Duléry R, Michallet M, Delage J, Lewalle P, Morschhauser F, Salles G, Yakoub-Agha I, Cornillon J. [Use of alternative donors for allogeneic haematopoietic cell transplantation in lymphoid neoplasms: Guidelines from the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC)]. Bull Cancer. 2017;

Genay S, Decaudin B, Ethgen S, Alluin A, Babol E, Labreuche J, Behal H, Vantyghem MC, Odou P, Lebuffe G. Effect of insulin infusion line on glycaemic variability in a perioperative high dependency unit (HDU): a prospective randomised controlled trial. Ann Intensive Care. 2017;7.

Genay S, Feutry F, Masse M, Barthélémy C, Sautou V, Odou P, Décaudin B, Azaroual N. Identification and quantification by H-1 nuclear magnetic resonance spectroscopy of seven plasticizers in PVC medical devices. Anal Bioanal Chem. 2017;409:1271–80.

Haybrard J, Simon N, Danel C, Pincon C, Barthelemy C, Tessier FJ, Decaudin B, Boulanger E, Odou P. Factors Generating Glucose Degradation Products In Sterile Glucose Solutions For Infusion: Statistical Relevance Determination Of Their Impacts. Sci Rep. 2017;7.

Henry H, Lannoy D, Simon N, Seguy D, D’Herbomez M, Barthélémy C, Décaudin B, Dine T, Odou P. Immunoassay quantification of human insulin added to ternary parenteral nutrition containers: comparison of two methods. Anal Bioanal Chem. 2017;409:3677–84.

Herbaux C, Bertrand E, Marot G, Roumier C, Poret N, Soenen V, Nibourel O, Roche-Lestienne C, Broucqsault N, Galiegue-Zouitina S, Boyle EM, Fouquet G, Renneville A, Tricot S, Morschhauser F, Preudhomme C, Quesnel B, Poulain S, Leleu X. BACH2 promotes indolent clinical presentation in Waldenstrom macroglobulinemia. Oncotarget. 2017;8:57451–9.

Herbaux C, Gauthier J, Brice P, Drumez E, Ysebaert L, Doyen H, Fornecker L, Bouabdallah K, Manson G, Ghesquières H, Tabrizi R, Hermet E, Lazarovici J, Thiebaut-Bertrand A, Chauchet A, Demarquette H, Boyle E, Houot R, Yakoub-Agha I, Morschhauser F. Efficacy and tolerability of nivolumab after allogeneic transplantation for relapsed Hodgkin lymphoma. Blood. 2017;129:2471–8.

Kahan BC, Koulenti D, Arvaniti K, Beavis V, Campbell D, Chan M, Moreno R, Pearse RM. Critical care admission following elective surgery was not associated with survival benefit: prospective analysis of data from 27 countries. Intensive Care Med. 2017;43:971–9.

Lefebvre M, Simon N, Vasseur M, Sidikou O, Barthélémy C, Décaudin B, Odou P. Evaluation of Specific Administering Devices for Antineoplastic Drugs Compounded in Syringes in Paediatry: Methodology Proposal. J Oncol Pharm Pract. 2017;1078155217733323.

Le Gouill S, Thieblemont C, Oberic L, Moreau A, Bouabdallah K, Dartigeas C, Damaj G, Gastinne T, Ribrag V, Feugier P, Casasnovas O, Zerazhi H, Haioun C, Maisonneuve H, Houot R, Jardin F, Van Den Neste E, Tournilhac O, Le Dû K, Morschhauser F, Cartron G, Fornecker LM, Canioni D, Callanan M, Béné MC, Salles G, Tilly H, Lamy T, Gressin R, Hermine O. Rituximab after Autologous Stem-Cell Transplantation in Mantle-Cell Lymphoma. N Engl J Med. 2017;377:1250–60.

Maiguy-Foinard A, Genay S, Lannoy D, Barthélémy C, Lebuffe G, Debaene B, Odou P, Décaudin B. Criteria for choosing an intravenous infusion line intended for multidrug infusion in anaesthesia and intensive care units. Anaesth Crit Care Pain Med. 2017;36:53–63.

Masse M, Genay S, Feutry F, Simon N, Barthélémy C, Sautou V, Décaudin B, Odou P, For The Armed Study Group. How to solve the problem of co-elution between two compounds in liquid chromatography through the first UV derivative spectrum. A trial on alternative plasticizers to di(2-ethylhexyl) phthalate. Talanta. 2017;162:187–92.

Noy A, de Vos S, Thieblemont C, Martin P, Flowers CR, Morschhauser F, Collins GP, Ma S, Coleman M, Peles S, Smith S, Barrientos JC, Smith A, Munneke B, Dimery I, Beaupre DM, Chen R. Targeting Bruton tyrosine kinase with ibrutinib in relapsed/refractory marginal zone lymphoma. Blood. 2017;129:2224–32.

Painchart L, Odou P, Bussières JF. [Particulate contamination associated with the manipulation of drugs in glass ampules: A literature review]. Ann Pharm Fr. 2017;

Parent M, Boudier A, Maincent P, Gibot S, Ait-Oufella H, Boufenzer A, Jolly L, Derive M, Kouach M, Goossens JF, Leroy P, Clarot I. LR12-peptide quantitation in whole blood by RP-HPLC and intrinsic fluorescence detection: Validation and pharmacokinetic study. Biomed Chromatogr. 2017;31.

Patin F, Corcia P, Vourc’h P, Nadal-Desbarats L, Baranek T, Goossens JF, Marouillat S, Dessein AF, Descat A, Madji Hounoum B, Bruno C, Leman S, Andres CR, Blasco H. Omics to Explore Amyotrophic Lateral Sclerosis Evolution: the Central Role of Arginine and Proline Metabolism. Mol Neurobiol. 2017;54:5361–74.

Perez M, Décaudin B, Maiguy-Foinard A, Barthélémy C, Lebuffe G, Storme L, Odou P. Dynamic Image Analysis To Evaluate Subvisible Particles During Continuous Drug Infusion In a Neonatal Intensive Care Unit. Sci Rep. 2017;7.

Ribrag V, Kim WS, Bouabdallah R, Lim ST, Coiffier B, Illes A, Lemieux B, Dyer MJ, Offner F, Felloussi Z, Kloos I, Luan Y, Vezan R, Graef T, Morschhauser F. Safety and efficacy of abexinostat, a pan-histone deacetylase inhibitor, in non-Hodgkin lymphoma and chronic lymphocytic leukemia: results of a phase II study. Haematologica. 2017;102:903–9.

Rogez-Florent T, Foulon C, Drucbert AS, Schifano N, Six P, Devassine S, Depreux P, Danzé PM, Goossens L, Danel C, Goossens JF. Chiral separation of new sulfonamide derivatives and evaluation of their enantioselective affinity for human carbonic anhydrase II by microscale thermophoresis and surface plasmon resonance. J Pharm Biomed Anal. 2017;137:113–22.

Shi Q, Flowers CR, Hiddemann W, Marcus R, Herold M, Hagenbeek A, Kimby E, Hochster H, Vitolo U, Peterson BA, Gyan E, Ghielmini M, Nielsen T, De Bedout S, Fu T, Valente N, Fowler NH, Hoster E, Ladetto M, Morschhauser F, Zucca E, Salles G, Sargent DJ. Thirty-Month Complete Response as a Surrogate End Point in First-Line Follicular Lymphoma Therapy: An Individual Patient-Level Analysis of Multiple Randomized Trials. J Clin Oncol. 2017;35:552–+.

Simon N, Coiteux V, Bruno B, Taque S, Charbonnier A, Souchet L, Vincent L, Yakoub-Agha I, Chalandon Y. [Dose adaptation of the drugs used for hematopoietic stem-cell transplantation in patients with comorbidity: Obesity, chronic renal disease or hepatopathy: Guidelines from the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC)]. Bull Cancer. 2017;

Teodorescu F, Quéniat G, Foulon C, Lecoeur M, Barras A, Boulahneche S, Medjram MS, Hubert T, Abderrahmani A, Boukherroub R, Szunerits S. Transdermal skin patch based on reduced graphene oxide: A new approach for photothermal triggered permeation of ondansetron across porcine skin. J Control Release. 2017;245:137–46.

Thieblemont C, Tilly H, Gomes da Silva M, Casasnovas RO, Fruchart C, Morschhauser F, Haioun C, Lazarovici J, Grosicka A, Perrot A, Trotman J, Sebban C, Caballero D, Greil R, van Eygen K, Cohen AM, Gonzalez H, Bouabdallah R, Oberic L, Corront B, Choufi B, Lopez-Guillermo A, Catalano J, Van Hoof A, Briere J, Cabeçadas J, Salles G, Gaulard P, Bosly A, Coiffier B. Lenalidomide Maintenance Compared With Placebo in Responding Elderly Patients With Diffuse Large B-Cell Lymphoma Treated With First-Line Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone. J Clin Oncol. 2017;35:2473–+.

Tout M, Casasnovas O, Meignan M, Lamy T, Morschhauser F, Salles G, Gyan E, Haioun C, Mercier M, Feugier P, Boussetta S, Paintaud G, Ternant D, Cartron G. Rituximab exposure is influenced by baseline metabolic tumor volume and predicts outcome of DLBCL patients: a Lymphoma Study Association report. Blood. 2017;129:2616–23.

Trappe RU, Dierickx D, Zimmermann H, Morschhauser F, Mollee P, Zaucha JM, Dreyling MH, Duhrsen U, Reinke P, Verhoef G, Subklewe M, Huttmann A, Tousseyn T, Salles G, Kliem V, Hauser IA, Tarella C, Van Den Neste E, Gheysens O, Anagnostopoulos I, Leblond V, Riess H, Choquet S. Response to Rituximab Induction Is a Predictive Marker in B-Cell Post-Transplant Lymphoproliferative Disorder and Allows Successful Stratification Into Rituximab or R-CHOP Consolidation in an International, Prospective, Multicenter Phase II Trial. J Clin Oncol. 2017;35:536–+.

Truant S, Baillet C, Deshorgue AC, El Amrani M, Huglo D, Pruvot FR. Contribution of hepatobiliary scintigraphy in assessing ALPPS most suited timing. Updates Surg. 2017;

von Tresckow B, Morschhauser F, Szer J, Eichenauer DA, Abramson JS, Sureda A, Engert A. Panobinostat consolidation in patients with Hodgkin lymphoma at risk for relapse after high dose chemotherapy and autologous stem cell transplant: final results after early trial discontinuation. Leuk Lymphoma. 2017;58:222–5.

Walter HS, Jayne S, Rule SA, Cartron G, Morschhauser F, Macip S, Karlin L, Jones C, Herbaux C, Quittet P, Shah N, Hutchinson CV, Fegan C, Yang Y, Mitra S, Salles G, Dyer MJ. Long-term follow-up of patients with CLL treated with the selective Bruton’s tyrosine kinase inhibitor ONO/GS-4059. Blood. 2017;129:2808–10.

Xerri L, Huet S, Venstrom JM, Szafer-Glusman E, Fabiani B, Canioni D, Chassagne-Clément C, Dartigues-Cuilléres P, Charlotte F, Laurent C, Gelas-Dore B, Bolen CR, Punnoose E, Bouabdallah R, Brice P, Morschhauser F, Cartron G, Olive D, Salles G. Rituximab treatment circumvents the prognostic impact of tumor-infiltrating T-cells in follicular lymphoma patients. Hum Pathol. 2017;64:128–36.

Younes A, Ansell S, Fowler N, Wilson W, de Vos S, Seymour J, Advani R, Forero A, Morschhauser F, Kersten MJ, Tobinai K, Zinzani PL, Zucca E, Abramson J, Vose J. The landscape of new drugs in lymphoma. Nat Rev Clin Oncol. 2017;14:335–46.

Younes A, Hilden P, Coiffier B, Hagenbeek A, Salles G, Wilson W, Seymour JF, Kelly K, Gribben J, Pfreunschuh M, Morschhauser F, Schoder H, Zelenetz AD, Rademaker J, Advani R, Valente N, Fortpied C, Witzig TE, Sehn LH, Engert A, Fisher RI, Zinzani PL, Federico M, Hutchings M, Bollard C, Trneny M, Elsayed YA, Tobinai K, Abramson JS, Fowler N, Goy A, Smith M, Ansell S, Kuruvilla J, Dreyling M, Thieblemont C, Little RF, Aurer I, Van Oers MH, Takeshita K, Gopal A, Rule S, de Vos S, Kloos I, Kaminski MS, Meignan M, Schwartz LH, Leonard JP, Schuster SJ, Seshan VE. International Working Group consensus response evaluation criteria in lymphoma (RECIL 2017). Ann Oncol. 2017;28:1436–47.

Zelenetz AD, Barrientos JC, Brown JR, Coiffier B, Delgado J, Egyed M, Ghia P, Illés Á, Jurczak W, Marlton P, Montillo M, Morschhauser F, Pristupa AS, Robak T, Sharman JP, Simpson D, Smolej L, Tausch E, Adewoye AH, Dreiling LK, Kim Y, Stilgenbauer S, Hillmen P. Idelalisib or placebo in combination with bendamustine and rituximab in patients with relapsed or refractory chronic lymphocytic leukaemia: interim results from a phase 3, randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2017;18:297–311.

Zucca E, Conconi A, Martinelli G, Bouabdallah R, Tucci A, Vitolo U, Martelli M, Pettengell R, Salles G, Sebban C, Guillermo AL, Pinotti G, Devizzi L, Morschhauser F, Tilly H, Torri V, Hohaus S, Ferreri AJ, Zachée P, Bosly A, Haioun C, Stelitano C, Bellei M, Ponzoni M, Copie-Bergman C, Jack A, Campo E, Mazzucchelli L, Cavalli F, Johnson P, Thieblemont C. Final Results of the IELSG-19 Randomized Trial of Mucosa-Associated Lymphoid Tissue Lymphoma: Improved Event-Free and Progression-Free Survival With Rituximab Plus Chlorambucil Versus Either Chlorambucil or Rituximab Monotherapy. J Clin Oncol. 2017;35:1905–+.